

**LUNSUMIO Vials 1 mg/1 ml**Version  
1.0Revision Date:  
06/10/2025Date of last issue: -  
Date of first issue: 06/10/2025**SECTION 1. IDENTIFICATION**

Product name : LUNSUMIO Vials 1 mg/1 ml

Product code : RO703-0816/F02-03

Common name(s),  
synonym(s) of the substance : anti-CD20/CD3 TDB  
Bispecific human anti-CD20/CD3 TDB antibody

**Manufacturer or supplier's details**

Company name of supplier : Genentech, Inc.

Address : 1 DNA Way  
South San Francisco, CA 94080  
USA

Telephone : 001-(650) 225-1000

E-mail address : info.sds@roche.com

Emergency telephone

In case of emergencies: : US CHEMTREC PHONE (800)-424-9300

**Recommended use of the chemical and restrictions on use**

Recommended use : Formulated pharmaceutical active substance

**SECTION 2. HAZARDS IDENTIFICATION****GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)**

Hazardous properties cannot be ruled out. Always exercise caution and follow good industrial hygiene practices when handling chemicals.

Not a hazardous substance or mixture.

**GHS label elements**

Hazardous properties cannot be ruled out. Always exercise caution and follow good industrial hygiene practices when handling chemicals.

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

**Other hazards**

None known.

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

| Chemical name                        | CAS-No.      | Concentration (% w/w) |
|--------------------------------------|--------------|-----------------------|
| Mosunetuzumab                        | 1905409-39-3 | 0.1                   |
| .alpha.-D-Glucopyranoside, .beta.-D- | 57-50-1      | 8.2                   |

# SAFETY DATA SHEET

## LUNSUMIO Vials 1 mg/1 ml

Version  
1.0

Revision Date:  
06/10/2025

Date of last issue: -  
Date of first issue: 06/10/2025

|  |           |      |
|--|-----------|------|
| fructofuranosyl  |           |      |
| L-Histidine  | 71-00-1   | 0.16 |
| L-Methionine   | 63-68-3   | 0.15 |
| Sorbitan, monododecanoate,<br>poly(oxy-1,2-ethanediyl) derivs. | 9005-64-5 | 0.1  |
| Acetic acid  | 64-19-7   | 0.1  |
| Water  | 7732-18-5 | 91   |

### SECTION 4. FIRST AID MEASURES

|   |   |
|---|---|
| General advice  | : Do not leave the victim unattended.   |
| If inhaled  | : If unconscious, place in recovery position and seek medical advice.<br>If symptoms persist, call a physician.   |
| In case of skin contact                                     | : Wash off with soap and water.   |
| In case of eye contact                                      | : Remove contact lenses.<br>Protect unharmed eye.<br>If eye irritation persists, consult a specialist.  |
| If swallowed  | : Keep respiratory tract clear.<br>Do not give milk or alcoholic beverages.<br>Never give anything by mouth to an unconscious person.<br>If symptoms persist, call a physician. |
| Most important symptoms and effects, both acute and delayed | : None known.   |
| Protection of first-aiders                                  | : First Aid responders should pay attention to self-protection and use the recommended protective clothing  |
| Notes to physician  | : Treat symptomatically.  |

### SECTION 5. FIRE-FIGHTING MEASURES

|                                       |   |
|---------------------------------------|---|
| Suitable extinguishing media          | : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. |
| Unsuitable extinguishing media        | : High volume water jet   |
| Specific hazards during fire fighting | : No information available.   |
| Hazardous combustion products         | : No hazardous combustion products are known  |

**LUNSUMIO Vials 1 mg/1 ml**Version  
1.0Revision Date:  
06/10/2025Date of last issue: -  
Date of first issue: 06/10/2025

Further information : Standard procedure for chemical fires.  
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Special protective equipment for fire-fighters : Wear self-contained breathing apparatus for firefighting if necessary.

---

**SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protective equipment and emergency procedures : Refer to protective measures listed in sections 7 and 8.

Environmental precautions : If the product contaminates rivers and lakes or drains inform respective authorities.

Methods and materials for containment and cleaning up : Wipe up with absorbent material (e.g. cloth, fleece).  
Keep in suitable, closed containers for disposal.

---

**SECTION 7. HANDLING AND STORAGE**

Advice on protection against fire and explosion : Normal measures for preventive fire protection.

Advice on safe handling : For personal protection see section 8.  
Smoking, eating and drinking should be prohibited in the application area.

Conditions for safe storage : Protect from heat and light  
  
Electrical installations / working materials must comply with the technological safety standards.

Materials to avoid : No materials to be especially mentioned.

Storage temperature : Protect from heat and light

Further information on storage stability : No decomposition if stored and applied as directed.

Packaging material : Suitable material: Ampoules, Prefilled syringes, Vials, Stainless steel, glass

---

**SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION****Ingredients with workplace control parameters**

| Components | CAS-No. | Value type<br>(Form of exposure) | Control parameters / Permissible | Basis |
|------------|---------|----------------------------------|----------------------------------|-------|
|            |         |                                  |                                  |       |

## SAFETY DATA SHEET

## LUNSUMIO Vials 1 mg/1 ml

 Version  
 1.0

 Revision Date:  
 06/10/2025

 Date of last issue: -  
 Date of first issue: 06/10/2025

|  |              |                                      | concentration |   |
|--|--------------|--------------------------------------|---------------|---|
| .alpha.-D-Glucopyranoside,<br>.beta.-D-fructofuranosyl | 57-50-1      | TWA                                  | 10 mg/m3      | ACGIH   |
|  |              | TWA<br>(Respirable)                  | 5 mg/m3       | NIOSH REL   |
|  |              | TWA (total)                          | 10 mg/m3      | NIOSH REL   |
|  |              | TWA (total<br>dust)                  | 15 mg/m3      | OSHA Z-1  |
|  |              | TWA<br>(respirable<br>fraction)      | 5 mg/m3       | OSHA Z-1  |
|  |              | TWA (Total<br>dust)                  | 15 mg/m3      | OSHA P0   |
|  |              | TWA<br>(respirable<br>dust fraction) | 5 mg/m3       | OSHA P0   |
| Mosunetuzumab  | 1905409-39-3 | IOEL                                 | 0.004 mg/m3   | Roche<br>Industrial<br>Hygiene<br>Committee<br>(RIHC) |

**Personal protective equipment**

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

## Hand protection

In case of contact through splashing:

Material : Nitrile rubber  
 Break through time : > 30 min  
 Glove thickness : > 0.11 mm

In case of full contact:

Material : butyl-rubber  
 Break through time : > 480 min  
 Glove thickness : > 0.4 mm

Remarks : Wear appropriate protective gloves to prevent skin contact.  
 Replace torn or punctured gloves promptly.

Eye protection : Safety glasses

Skin and body protection : Protective suit

Hygiene measures : General industrial hygiene practice.

**LUNSUMIO Vials 1 mg/1 ml**Version  
1.0Revision Date:  
06/10/2025Date of last issue: -  
Date of first issue: 06/10/2025

---

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

|  |                     |
|--|---------------------|
| Appearance                                       | : Clear liquid      |
| Color  | : colorless         |
| Odor   | : No data available |
| Odor Threshold                                   | : No data available |
| pH   | : 5.8               |
| Melting point/ range                             | : No data available |
| Boiling point/boiling range                      | : No data available |
| Flash point                                      | : No data available |
| Evaporation rate                                 | : No data available |
| Self-ignition                                    | : Not applicable    |
| Upper explosion limit / Upper flammability limit | : No data available |
| Lower explosion limit / Lower flammability limit | : No data available |
| Vapor pressure                                   | : No data available |
| Relative vapor density                           | : No data available |
| Relative density                                 | : No data available |
| Density  | : No data available |
| Solubility(ies)                                  |                     |
| Water solubility                                 | : No data available |
| Solubility in other solvents                     | : No data available |
| Partition coefficient: n-octanol/water           | : No data available |
| Autoignition temperature                         | : No data available |
| Decomposition temperature                        | : No data available |

**LUNSUMIO Vials 1 mg/1 ml**Version  
1.0Revision Date:  
06/10/2025Date of last issue: -  
Date of first issue: 06/10/2025

Viscosity  
Viscosity, dynamic : No data available  
Viscosity, kinematic : No data available  
Explosive properties : No data available  
Oxidizing properties : No data available  
Particle characteristics  
Particle Size Distribution : Not applicable

---

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity : No dangerous reaction known under conditions of normal use.

Chemical stability : Proteins are temperature-sensitive; the thermal denaturation has an impact on quality but does not affect Plant and Process Safety; during decomposition no flammable gas, no organic peroxide and no oxidising substances are created  
Stable under normal conditions.

Possibility of hazardous reactions : No data available  
Stable under recommended storage conditions.  
No hazards to be specially mentioned.

Conditions to avoid : No data available  
No data available

Incompatible materials : No data available  
Not applicable

Hazardous decomposition products : No decomposition if stored and applied as directed.  
No hazardous decomposition products are known.

---

**SECTION 11. TOXICOLOGICAL INFORMATION****Acute toxicity**

Not classified due to lack of data.

**Components:****Mosunetuzumab:**

Acute oral toxicity : Remarks: Not bioavailable by oral administration

Acute toxicity (other routes of administration) : HNSTD (Highest Non-Severely Toxic Dose) (cynomolgus monkey): > 1 mg/kg  
Application Route: i.v.  
GLP: yes

**LUNSUMIO Vials 1 mg/1 ml**Version  
1.0Revision Date:  
06/10/2025Date of last issue: -  
Date of first issue: 06/10/2025**.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Acute oral toxicity : LD50 Oral (Rat): 29,700 mg/kg

**L-Histidine:**

Acute oral toxicity : LD50 Oral (Rat): &gt; 15,000 mg/kg

LD50 Oral (Mouse): &gt; 15,000 mg/kg

**L-Methionine:**Acute oral toxicity : Acute toxicity estimate (Rat): > 5,000 mg/kg  
Method: Expert judgmentAcute toxicity estimate (Mouse): > 5,000 mg/kg  
Method: Expert judgmentAcute inhalation toxicity : Acute toxicity estimate: > 30 mg/l  
Test atmosphere: dust/mist  
Method: Expert judgmentAcute dermal toxicity : Acute toxicity estimate: > 5,000 mg/kg  
Method: Expert judgment**Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.:**

Acute oral toxicity : LD50 Oral (Rat): 38,900 mg/kg

**Acetic acid:**Acute oral toxicity : LD50 Oral (Rat, male and female): 3,310 mg/kg  
GLP: noAcute inhalation toxicity : LC50 (Rat, male and female): 11.4 mg/l  
Exposure time: 4 h  
Test atmosphere: vapor  
GLP: no  
Assessment: The substance or mixture has no acute inhalation toxicity

**LUNSUMIO Vials 1 mg/1 ml**Version  
1.0Revision Date:  
06/10/2025Date of last issue: -  
Date of first issue: 06/10/2025**Skin corrosion/irritation**

Not classified due to lack of data.

**Components:****L-Histidine:**

|         |                                       |
|---------|---------------------------------------|
| Species | : reconstructed human epidermis (RhE) |
| Method  | : OECD Test Guideline 439             |
| Result  | : No skin irritation                  |
| GLP     | : yes                                 |

**L-Methionine:**

Remarks : This information is not available.

**Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.:**

|         |                      |
|---------|----------------------|
| Species | : Rabbit             |
| Result  | : No skin irritation |

**Acetic acid:**

|               |                             |
|---------------|-----------------------------|
| Species       | : Rabbit                    |
| Exposure time | : 4 h                       |
| Method        | : OECD Test Guideline 404   |
| Result        | : Causes severe burns.      |
| GLP           | : No information available. |

**Serious eye damage/eye irritation**

Not classified due to lack of data.

**Components:****L-Histidine:**

|         |                           |
|---------|---------------------------|
| Species | : Bovine cornea           |
| Result  | : No eye irritation       |
| Method  | : OECD Test Guideline 437 |

**L-Methionine:**

Remarks : This information is not available.



**LUNSUMIO Vials 1 mg/1 ml**Version  
1.0Revision Date:  
06/10/2025Date of last issue: -  
Date of first issue: 06/10/2025**Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.:**

Species : Rabbit  
Result : No eye irritation

**Acetic acid:**

Species : Rabbit  
Result : Risk of serious damage to eyes.  
Exposure time : 4 h  
Method : OECD Test Guideline 405  
GLP : No information available.

**Respiratory or skin sensitization****Skin sensitization**

Not classified due to lack of data.

**Respiratory sensitization**

Not classified due to lack of data.

**Components:****Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.:**

Species : Guinea pig  
Result : Not a skin sensitizer.

**Germ cell mutagenicity**

Not classified due to lack of data.

**Components:****.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
Result: negative

**Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.:**

Genotoxicity in vitro : Test Type: Micronucleus test  
Test system: Escherichia coli  
Result: negative

Germ cell mutagenicity - Assessment : Tests on bacterial or mammalian cell cultures did not show mutagenic effects.

**Acetic acid:**

Genotoxicity in vitro : Test Type: Microbial mutagenesis assay (Ames test)

**LUNSUMIO Vials 1 mg/1 ml**Version  
1.0Revision Date:  
06/10/2025Date of last issue: -  
Date of first issue: 06/10/2025

Test system: Salmonella typhimurium  
Metabolic activation: Metabolic activation  
Method: OECD Test Guideline 471  
Result: negative  
GLP: No information available.  
Remarks: In vitro tests did not show mutagenic effects

Test Type: Chromosome aberration test in vitro  
Test system: Chinese hamster ovary cells  
Metabolic activation: with and without metabolic activation  
Method: OECD Test Guideline 473  
Result: negative  
GLP: no  
Remarks: In vitro tests did not show mutagenic effects

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Rat (male and female)  
Application Route: Inhalation  
Exposure time: 13 weeks  
Dose: 0, 1, 5, 20 ppm  
Method: Mutagenicity (micronucleus test)  
Result: negative  
GLP: yes

**Carcinogenicity**

Not classified due to lack of data.

**Components:****.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Remarks : No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**L-Histidine:**

Remarks : No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.:**

Remarks : No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**LUNSUMIO Vials 1 mg/1 ml**Version  
1.0Revision Date:  
06/10/2025Date of last issue: -  
Date of first issue: 06/10/2025**Acetic acid:**

Species : Mouse, female  
Application Route : Dermal  
Exposure time : 32 weeks  
Result : negative  
GLP : no  
Remarks : No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**IARC** No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**OSHA** No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

**NTP** No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

**Reproductive toxicity**

Not classified due to lack of data.

**Components:****Mosunetuzumab:**

Effects on fertility : Species: cynomolgus monkey  
Result: No adverse effects.

**Acetic acid:**

Effects on fetal development : Species: Mouse, female  
Application Route: Oral  
Dose: 10 ml/kg body weight  
Duration of Single Treatment: 6 - 15 d  
Developmental Toxicity: NOAEL: 345 mg/kg body weight  
Method: Regulation (EC) No. 440/2008, Annex, B.31  
GLP: No information available.

**STOT-single exposure**

Not classified due to lack of data.

**Components:****.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Assessment : The substance or mixture is not classified as specific target organ toxicant, single exposure.

**LUNSUMIO Vials 1 mg/1 ml**Version  
1.0Revision Date:  
06/10/2025Date of last issue: -  
Date of first issue: 06/10/2025**L-Methionine:**

Assessment : The substance or mixture is not classified as specific target organ toxicant, single exposure.

**STOT-repeated exposure**

Not classified due to lack of data.

**Components:****.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Assessment : The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

**L-Methionine:**

Assessment : The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

**Aspiration toxicity**

Not classified due to lack of data.

**Components:****.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

No data available

**L-Methionine:**

No data available

**Further information****Product:**

Remarks : No data available

**Components:****Mosunetuzumab:**

Remarks : after parenteral application, rare cases of hypersensitivity, including anaphylactic shock, can occur

**.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Remarks : Health injuries are not known or expected under normal use.

**LUNSUMIO Vials 1 mg/1 ml**Version  
1.0Revision Date:  
06/10/2025Date of last issue: -  
Date of first issue: 06/10/2025**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:****Ecotoxicology Assessment**

Acute aquatic toxicity : This product has no known ecotoxicological effects.

Chronic aquatic toxicity : This product has no known ecotoxicological effects.

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to  
the environment : No data available**L-Histidine:**Toxicity to daphnia and other  
aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l  
Exposure time: 48 h  
Test Type: static test  
Method: OECD Test Guideline 202  
GLP: yesToxicity to algae/aquatic  
plants : EC50 (Desmodesmus subspicatus (green algae)): > 100 mg/l  
End point: Growth inhibition  
Exposure time: 72 h  
Test Type: static test  
Method: OECD Test Guideline 201  
GLP: yesToxicity to microorganisms : EC10 (activated sludge): > 200 mg/l  
Exposure time: 5 d  
GLP: no**L-Methionine:**Toxicity to fish : LC50 : > 100 mg/l  
Exposure time: 96 h**Ecotoxicology Assessment**

Acute aquatic toxicity : This product has no known ecotoxicological effects.

Chronic aquatic toxicity : This product has no known ecotoxicological effects.

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to  
the environment : No data available**Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.:**Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 216 mg/l  
Exposure time: 96 h

**LUNSUMIO Vials 1 mg/1 ml**Version  
1.0Revision Date:  
06/10/2025Date of last issue: -  
Date of first issue: 06/10/2025

LC50 (Brachydanio rerio (zebrafish)): > 100 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203  
GLP: yes

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l  
Exposure time: 48 h

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOELR (Daphnia): 10 mg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211

Toxicity to microorganisms : EC0 (Pseudomonas putida): > 10,000 mg/l  
  
EC50 (Bacteria): 774 mg/l  
Exposure time: 5 h

**Acetic acid:**

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 300.82 mg/l  
End point: mortality  
Exposure time: 96 h  
Test Type: semi-static test  
Analytical monitoring: no  
Method: OECD Test Guideline 203  
GLP: yes

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 300.82 mg/l  
End point: Immobilization  
Exposure time: 48 h  
Test Type: static test  
Analytical monitoring: yes  
Method: OECD Test Guideline 202  
GLP: yes

Toxicity to algae/aquatic plants : EC50 (Skeletonema costatum (marine diatom)): > 300.82 mg/l  
Exposure time: 72 h  
Test Type: static test  
Analytical monitoring: no  
GLP: yes

**Persistence and degradability****Components:****Mosunetuzumab:**

Biodegradability : Result: Globular proteins are generally well biodegradable

**Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.:**

Biodegradability : Result: Readily biodegradable.  
Biodegradation: > 70 %  
Exposure time: 28 d  
Method: OECD Test Guideline 301B

**LUNSUMIO Vials 1 mg/1 ml**Version  
1.0Revision Date:  
06/10/2025Date of last issue: -  
Date of first issue: 06/10/2025**Acetic acid:**

Biodegradability : aerobic  
Inoculum: activated sludge  
Concentration: 3 mg/l  
Result: Readily biodegradable.  
Biodegradation: 96 %  
Exposure time: 20 d  
GLP: no

**Bioaccumulative potential****Components:****Mosunetuzumab:**

Partition coefficient: n- : Remarks: No data available  
octanol/water

**.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**

Partition coefficient: n- : log Pow: -3.7 (68 °F / 20 °C)  
octanol/water

**L-Histidine:**

Partition coefficient: n- : log Pow: ca. -3.32  
octanol/water

**L-Methionine:**

Partition coefficient: n- : log Pow: -1.87  
octanol/water

**Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.:**

Bioaccumulation : Remarks: No data available

Partition coefficient: n- : Remarks: No data available  
octanol/water

**Acetic acid:**

Bioaccumulation : Bioconcentration factor (BCF): 3.16

Partition coefficient: n- : log Pow: -0.17 (77 °F / 25 °C)  
octanol/water pH: 7  
Method: No information available.  
GLP: No information available.

**Water:**

Partition coefficient: n- : Remarks: No data available  
octanol/water

**Mobility in soil**

No data available

**LUNSUMIO Vials 1 mg/1 ml**Version  
1.0Revision Date:  
06/10/2025Date of last issue: -  
Date of first issue: 06/10/2025**Other adverse effects****Product:**

Ozone-Depletion Potential : Regulation: 40 CFR Protection of Environment; Part 82  
Protection of Stratospheric Ozone - CAA Section 602 Class I  
Substances  
Remarks: This product neither contains, nor was  
manufactured with a Class I or Class II ODS as defined by the  
U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A +  
B).

Additional ecological  
information : No data available

**Components:****Mosunetuzumab:**

Additional ecological  
information : Monoclonal antibodies are proteins with highly specific affinity  
to a certain antigen; therefore, no appreciable ecotoxic  
potential is to be expected

**L-Histidine:**

Additional ecological  
information : No data available

**L-Methionine:**

Adsorbed organic bound  
halogens (AOX) : Remarks: Not applicable

Additional ecological  
information : No data available

---

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues : Can be disposed as waste water, when in compliance with  
local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste  
handling site for recycling or disposal.

---

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

Not regulated as a dangerous good

**IATA-DGR**

Not regulated as a dangerous good

**IMDG-Code**



**LUNSUMIO Vials 1 mg/1 ml**Version  
1.0Revision Date:  
06/10/2025Date of last issue: -  
Date of first issue: 06/10/2025

Not regulated as a dangerous good

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**Domestic regulation****49 CFR**

Not regulated as a dangerous good

**Special precautions for user**Remarks : Not dangerous goods in the meaning of ADR/RID, ADN,  
IMDG-Code, ICAO/IATA-DGR**SECTION 15. REGULATORY INFORMATION****CERCLA Reportable Quantity**

Listed substances in the product are at low enough levels to not be expected to exceed the RQ

**SARA 304 Extremely Hazardous Substances Reportable Quantity**

This material does not contain any components with a section 304 EHS RQ.

**SARA 302 Extremely Hazardous Substances Threshold Planning Quantity**

| Components | CAS-No. | Component TPQ (lbs) |
|------------|---------|---------------------|
|------------|---------|---------------------|

**SARA 311/312 Hazards** : No SARA Hazards**Clean Air Act**

This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCM Intermediate or Final VOC's (40 CFR 60.489).

**Clean Water Act**

The following Hazardous Substances are listed under the U.S. CleanWater Act, Section 311, Table 116.4A:

Acetic acid 64-19-7  $\geq 0 - < 0.1 \%$ 

The following Hazardous Chemicals are listed under the U.S. CleanWater Act, Section 311, Table 117.3:

Acetic acid 64-19-7  $\geq 0 - < 0.1 \%$ 

This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307

This product does not contain any priority pollutants related to the U.S. Clean Water Act

**US State Regulations****Massachusetts Right To Know**

.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl 57-50-1

**Pennsylvania Right To Know**

Water 7732-18-5

.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl 57-50-1

Acetic acid 64-19-7

**LUNSUMIO Vials 1 mg/1 ml**Version  
1.0Revision Date:  
06/10/2025Date of last issue: -  
Date of first issue: 06/10/2025**Maine Chemicals of High Concern****Vermont Chemicals of High Concern****Washington Chemicals of High Concern****California Permissible Exposure Limits for Chemical Contaminants**

.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl 57-50-1

**The ingredients of this product are reported in the following inventories:**

|       |  |
|-------|--|
| AIIC  | : Not in compliance with the inventory   |
| DSL   | : This product contains the following components that are not on the Canadian DSL nor NDSL.<br><br>Mosunetuzumab |
| NZIoC | : On the inventory, or in compliance with the inventory  |
| ENCS  | : Not in compliance with the inventory   |
| ISHL  | : Not in compliance with the inventory   |
| KECI  | : Not in compliance with the inventory   |
| PICCS | : Not in compliance with the inventory   |
| IECSC | : Not in compliance with the inventory   |
| TCSI  | : Not in compliance with the inventory   |
| TSCA  | : Product contains substance(s) not listed on TSCA inventory.  |
| TECI  | : Not in compliance with the inventory   |


**TSCA list**

No substances are subject to a Significant New Use Rule.

No substances are subject to TSCA 12(b) export notification requirements.

---

**SECTION 16. OTHER INFORMATION****Further information**

**LUNSUMIO Vials 1 mg/1 ml**Version  
1.0Revision Date:  
06/10/2025Date of last issue: -  
Date of first issue: 06/10/2025**NFPA 704:****HMIS® IV:**

|                 |   |   |
|-----------------|---|---|
| HEALTH          | / | 0 |
| FLAMMABILITY    |   | 0 |
| PHYSICAL HAZARD |   | 0 |

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "\*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

**Full text of other abbreviations**

|                 |   |
|-----------------|---|
| ACGIH           | : USA. ACGIH Threshold Limit Values (TLV)   |
| NIOSH REL       | : USA. NIOSH Recommended Exposure Limits  |
| OSHA P0         | : USA. Table Z-1-A Limits for Air Contaminants (1989 vacated values)                        |
| OSHA Z-1        | : USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants          |
| ACGIH / TWA     | : 8-hour, time-weighted average   |
| NIOSH REL / TWA | : Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek |
| OSHA P0 / TWA   | : 8-hour time weighted average  |
| OSHA Z-1 / TWA  | : 8-hour time weighted average  |

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect

**LUNSUMIO Vials 1 mg/1 ml**Version  
1.0Revision Date:  
06/10/2025Date of last issue: -  
Date of first issue: 06/10/2025

Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECl - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Revision Date : 06/10/2025

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / EN / 2404